After a Lutathera treatment for a neuroendocrine tumor, your body gives off a small amount of radiation for a while, so most people are sent home with a few days of household precautions: sit down to use the toilet and flush twice, sleep in a separate bed, keep some distance from family and pets, and shower daily. The specifics come from your treatment center, and its written instructions take priority over any general list, including this one.
A peptide that carries radiation to the tumor
Lutathera (lutetium Lu 177 dotatate) is what doctors call peptide receptor radionuclide therapy. According to the FDA prescribing information, the drug is a small ring-shaped peptide, a version of the body’s own hormone somatostatin, attached through a chemical cage to radioactive lutetium-177. Many neuroendocrine tumor cells are covered in somatostatin receptors. The peptide latches onto those receptors, mainly the type called SSTR2, gets pulled inside the cell, and the radiation damages the tumor cell and its neighbors from within.
It is approved for adults and children 12 and older with somatostatin receptor-positive neuroendocrine tumors of the stomach, intestines and pancreas. In the NETTER-1 trial described on the label, 229 people with advanced midgut tumors received either Lutathera plus octreotide or high-dose octreotide alone. At the main analysis, the cancer had progressed or the patient had died in 23% of the Lutathera group versus 69% of the comparison group, and the risk of progression or death was about 79% lower. The trial was open-label, so patients and doctors knew who got which treatment, though scans were read by a blinded review committee.
Why the precautions exist and how long they last
The drug leaves the body mainly through the kidneys. The label reports that about 58% is excreted in urine within 24 hours and 65% within 48 hours, and that radiation can still be detected in urine for up to 30 days. Centers only send patients home once the expected exposure to other people is below regulatory limits, so the household rules are about keeping that small exposure as low as reasonably possible. The label also asks patients to drink fluids and urinate often the day before, the day of and the day after treatment.
The manufacturer’s radiation safety page for clinicians summarizes the common advice drawn from a consensus of nuclear medicine and neuroendocrine tumor societies and from Mayo Clinic:
- Bathroom: for at least 3 days, use the toilet sitting down, even men, and flush twice. The patient site adds that anyone helping in the bathroom should wear gloves.
- Hygiene and laundry: shower daily for at least 7 days, and for 3 days use your own towels and wash your clothes separately.
- Sleep and closeness: for at least 3 days, sleep in a separate bed and avoid intimate contact.
- Distance: for at least 3 days, stay no closer than about 3 feet to others for more than an hour a day, aim for 6 feet, and limit public transportation. The patient site includes pets in that distance advice.
Households with babies, young children or a pregnant person should ask the center for tailored instructions before the treatment day, since plans for childcare may need to be made in advance.
Pregnancy, breastfeeding and fertility
The label warns that Lutathera can harm a developing baby. Women who could become pregnant need a pregnancy check before treatment and should use effective birth control during treatment and for 7 months after the last dose; men with partners who could become pregnant are advised to use it for 4 months. Breastfeeding should stop during treatment and for 2.5 months after the last dose. The cumulative radiation to the ovaries and testes is in a range where temporary or permanent infertility can occur, which is worth raising before the first infusion if future children matter to you.
What to report between treatments
Lutathera can lower blood counts. In NETTER-1, anemia occurred in 81% of patients and low platelets in 53%, mostly mild, so regular blood tests are part of care. Unusual bruising or bleeding, fever or infections, or a big drop in energy are worth a call. Rarely, within a day of the first infusion, tumors release a burst of hormones that causes flushing, diarrhea and low blood pressure, and the label also lists kidney and liver monitoring. Long-term radiation exposure also raises the risk of other cancers. In NETTER-1, myelodysplastic syndrome, a bone marrow disorder that can lead to leukemia, was reported in 2.3% of Lutathera patients over a median of about six years of follow-up, compared with none in the comparison group. That is a trade-off to discuss with your oncologist.
By The Everyday Brief · AI-assisted editorial. Drafted with AI research assistance; claims checked against the linked sources (fetched 2026-10-08 PT). Not medical advice.
Sources
- U.S. FDA: Lutathera (lutetium Lu 177 dotatate) prescribing information, revised April 2024 (PDF)
- Lutathera HCP site (Novartis/Advanced Accelerator Applications): Radiation safety counseling, summarizing NANETS/SNMMI consensus and Mayo Clinic recommendations
- Lutathera patient site (manufacturer): Side effects and safety, reducing radiation exposure after treatment